التفاصيل البيبلوغرافية
| العنوان: |
A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy. |
| المؤلفون: |
Liu, Shurong1 (AUTHOR), Tian, Ye1 (AUTHOR), Jiang, Sujun1 (AUTHOR), Wang, Zihua1 (AUTHOR) wangzh@fjmu.edu.cn |
| المصدر: |
International Journal of Molecular Sciences. Mar2023, Vol. 24 Issue 5, p4590. 10p. |
| مصطلحات موضوعية: |
*HER2 positive breast cancer, *CANCER treatment, *BREAST cancer, *BREAST, *PEPTIDES |
| مستخلص: |
Tumor-targeting peptide–drug conjugates (PDCs) have become a focus of research in recent years. However, due to the instability of peptides and their short in vivo effective half-life, they have limited clinical application. Herein, we propose a new DOX PDC based on a homodimer HER-2-targeting peptide and acid-sensitive hydrazone bond, which could enhance the anti-tumor effect of DOX and reduce systemic toxicities. The PDC could accurately deliver DOX into HER2-positive SKBR-3 cells, with it showing 2.9 times higher cellular uptake than free DOX and enhanced cytotoxicity with respect to IC50 of 140 nM (vs. 410 nM for free DOX). In vitro assays showed that the PDC had high cellular internalization efficiency and cytotoxicity. In vivo anti-tumor experiments indicated that the PDC could significantly inhibit the growth of HER2-positive breast cancer xenografts in mice and reduce the side effects of DOX. In summary, we constructed a novel PDC molecule targeting HER2-positive tumors, which may overcome some deficiencies of DOX in breast cancer therapy. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder